NOAH Compendium

Printed from NOAH Compendium ( (c) Copyright NOAH Compendium 2024. All Rights Reserved.
Date: Monday, May 20, 2024 6:56

Description: Zoetis logo
Release 2.157
Cazitel Plus XL Tablets for Dogs
Species: Dogs
Therapeutic indication: Pharmaceuticals: Endoparasiticides: Anthelmintics for dogs
Active ingredient: Febantel, Praziquantel, Pyrantel Embonate
Product:Cazitel® Plus XL Tablets for Dogs
Product index: Cazitel Plus XL
A yellow coloured, oblong tablet with a breakline on both sides, containing 175 mg praziquantel, 504 mg pyrantel embonate (equivalent to 175 mg pyrantel) and 525 mg febantel.
Indicated for the treatment of mixed infections by nematodes and cestodes of the following species in adult dogs:
Ascarids: Toxocara canis, Toxascaris leonina (adult and late immature forms).
Hookworms: Uncinaria stenocephala, Ancylostoma caninum (adults).
Whipworms: Trichuris vulpis (adults).
Tapeworms: Echinococcus species, (E. granulosus, E. multilocularis), Taenia species, (T. hydatigena, T. pisiformis, T. taeniformis), Dipylidium caninum (adult and immature forms).
Dosage and administration
Oral use.
The recommended dose rates are 15 mg/kg bodyweight febantel, 5 mg/kg pyrantel (equivalent to 14.4 mg/kg pyrantel embonate) and 5 mg/kg praziquantel. This is equivalent to 1 tablet per 35 kg bodyweight.
Dogs of > 35 kg bodyweight should be given 1 Cazitel Plus XL tablet plus the appropriate quantity of Cazitel Plus tablets equivalent to 1 tablet per 10 kg bodyweight.
Dogs weighing approximately 17.5 kg bodyweight should be given ½ Cazitel Plus XL tablet.
The tablets can be given directly to the dog or disguised in food. No starvation is needed before or after treatment.
To ensure a correct dosage, bodyweight should be determined as accurately as possible.
Dosage table (guide):
Bodyweight (kg)
Cazitel Plus XL Tablets
Cazitel Plus Tablets
Approx. 17.5
31 - 35
36 - 40
41 - 45
46 - 50
1 ½
51 - 55
56 - 60
2 ½
61 - 65
66 - 70
If there is a risk of re-infestation, the advice of a veterinarian should be sought regarding the need for and the frequency of repeat administration.
Contra-indications, warnings, etc
Do not use simultaneously with piperazine compounds as the anthelmintic effects of pyrantel and piperazine may be antagonized.
Do not use in cases of hypersensitivity to the active substances or to any of the excipients.
Fleas serve as intermediate hosts for one common type of tapeworm Dipylidium caninum. Tapeworm infestation is certain to reoccur unless control of intermediate hosts such as fleas, mice, etc. is undertaken.
Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy:
Too frequent and repeated use of anthelmintics from the same class, over an extended period of time;
Underdosing, which may be due to an underestimation of bodyweight, or misadministration of the product.
Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class.
Concurrent use with other cholinergic compounds can lead to toxicity.
Very rare
(<1 animal / 10,000 animals treated, including isolated reports)
Digestive tract disorder (diarrhoea, emesis)
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system.
Teratogenic effects attributed to high doses of febantel have been reported in sheep and rats. No studies have been performed in dogs during early pregnancy.
Use of the product during pregnancy should be in accordance with a benefit risk assessment by the responsible veterinarian. It is recommended that the product is not used in dogs during the first 4 weeks of pregnancy. Do not exceed the stated dose when treating pregnant bitches.
User warnings
In case of accidental ingestion, seek medical advice and show the package leaflet or the label to the physician.
In the interests of good hygiene, persons administering the tablets directly to the dog, or by adding them to the dog’s food, should wash their hands afterwards.
Echinococcosis represents a hazard for humans. As echinococcosis is a notifiable disease to the World Organisation for Animal Health (OIE), specific guidelines on the treatment and follow-up, and on the safeguard of persons, need to be obtained from the relevant competent authority.
Pharmaceutical precautions
This veterinary medicinal product does not require any special storage conditions.
Each time an unused tablet is stored, it should be returned to the open blister space and the blister inserted back into the outer carton. Unused half tablets must be used within 14 days.
Medicines should not be disposed of via wastewater. Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Keep out of the sight and reach of children.
For animal treatment only.
Legal category
Legal category: NFA-VPS
Packaging quantities
Cartons containing 50 tablets.
Further information
The combination of praziquantel, pyrantel embonate and febantel is well tolerated in dogs. In safety studies, a single dose of 5 times the recommended dose or greater gave rise to occasional vomiting.
Marketing Authorisation Holder (if different from distributor)
Chanelle Pharmaceuticals Manufacturing Ltd.
Marketing Authorisation Number
UK(GB): Vm 08749/5039
UK(NI): Vm 08749/3003
Significant changes
GTIN description:50 tablets: